Financial Performance - In 2024, the company's operating revenue was 153.76 million, a decrease of 28.97% compared to 2023 [2] - The net profit attributable to shareholders was 22.41 million, down 50.82% year-on-year [2] - The net profit after deducting non-recurring gains and losses was 10.91 million, a decline of 70.95% compared to the previous year [2] - The basic earnings per share were 0.32, a decrease of 52.94% from the previous year [2] Profitability Metrics - The gross profit margin for 2024 was 43.00%, down 4.16% from the previous year [3] - The net profit margin was 14.23%, a decrease of 6.34% year-on-year [3] Expense Management - Total operating expenses for the period were 42.75 million, a reduction of 8.02 million compared to the previous year [3] - The expense ratio increased to 27.80%, up 4.35% from the previous year [3] - Sales expenses decreased by 25.37%, management expenses decreased by 9.91%, R&D expenses decreased by 12.27%, and financial expenses decreased by 38.44% [3] Corporate Governance - The chairman of the company, Zhang Aijiang, received a salary of 681,200 [5] - Zhang Aijiang has a familial relationship with other key executives, including his daughter Zhang Jia and son-in-law Yan Qipeng [5] - The company was established on April 20, 2004, and is located in Jijiang, Jiangxi Province, focusing on the R&D, production, and sales of chemical raw materials and traditional Chinese medicine [5]
新赣江2024年净利腰斩，58岁董事长张爱江女儿女婿任副总、外甥任监事会主席